Judy Hemberger

Dr. Hemberger has more than thirty years of experience in the pharmaceutical industry. She was co-founder and COO of Pharmion Corporation prior to its sale to Celgene for $2.9 billion. Dr. Hemberger’s expertise includes clinical development, global regulatory and early commercialization of pharmaceutical products. She is a demonstrated leader of both domestic and international operations. Dr. Hemberger is highly effective at raising capital for start-up ventures, including private equity, initial public offerings, and secondary placements. She is a board member of a wide variety of health care companies, public and private, and has served as a consultant and partner in venture capital firms. In addition to her tenure at Pharmion, Dr. Hemberger has served as CEO of Zosano (formerly Macroflux) and as a Venture Partner for Nomura Phase 4 Ventures. She has served as a director on over 16 health care boards of directors. Dr. Hemberger is a graduate of Mt. St. Scholastic College (BS), University of Missouri (PhD), and Business Rockhurst College (MBA).